Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Quarterly Earnings Results

Recursion Pharmaceuticals (NASDAQ:RXRX) posted its quarterly earnings data on Monday. The company reported ($0.22) EPS for the quarter, hitting analysts’ consensus estimates of ($0.22), FiscalAI reports. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%. The company had revenue of $18.55 million for the quarter, compared to analyst estimates of $14.81 million. During the same quarter in the previous year, the firm earned ($0.36) earnings per share.

Recursion Pharmaceuticals Price Performance

RXRX opened at $3.83 on Tuesday. The company has a fifty day moving average price of $3.75 and a two-hundred day moving average price of $3.54. The firm has a market capitalization of $2.05 billion, a PE ratio of -3.68 and a beta of 1.04. Recursion Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $5.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, October 17th. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Morgan Stanley set a $5.90 target price on shares of Recursion Pharmaceuticals in a research note on Friday, October 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.18.

Insider Activity

In other news, CEO Najat Khan sold 22,408 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the transaction, the chief executive officer directly owned 2,072,890 shares in the company, valued at $7,296,572.80. This trade represents a 1.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the sale, the director directly owned 162,156 shares of the company’s stock, valued at approximately $810,780. This trade represents a 13.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 127,408 shares of company stock valued at $546,076 in the last 90 days. 6.65% of the stock is owned by company insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.